A lawsuit alleges the companies used “fraudulent” ads to lure customers and then switched their insurance plans and agents ...

The Medicare tax rate for 2025 remains consistent, reflecting the longstanding structure that funds Medicare, a critical ...

Shilpa Medicare’s Joint Venture Oncosol along with its partner Shorla Oncology announces that the USFDA has approved IMKELDI ...

Understanding Medicare basics may be one of the most maddening tasks you'll face when heading into retirement. Figuring out when to enroll in Medicare and which parts of Medicare to elect can be ...

On Nov. 26, CMS proposed reforms to the Medicare Advantage and Part D programs for contract year 2026, including changes to prior authorization and GLP-1 coverage. Here are 10 things ASC leaders and ...

Oncosol, along with its partner Shorla Oncology, has received US Food and Drug Administration (USFDA) approval for IMKELDI (imatinib oral solution) to treat leukemia and other cancers.

Federal officials announced Tuesday that audits they launched earlier this year have led to significant new reforms.

Officials want people to understand just how narrow their window to sign up for flexible gap-filler coverage is.

As officials put the change in draft rules for 2026, the incoming president's Medicare agency pick might support it.

The filing indicates the hospital has assets and liabilities ranging between $1m and $10m, with 50 to 99 creditors.

Shilpa Medicare has informed that the subject expert committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval ...